Loading clinical trials...
Loading clinical trials...
A French Open-label Extension Study of Canakinumab in Patients Who Participated in International Phase III Studies CACZ885G2301E1 or CACZ885G2306 in Systemic Juvenile Idiopathic Arthritis and CACZ885N2301 in Hereditary Periodic Fevers (TRAPS, HIDS, or crFMF)
Conditions
Interventions
canakinumab
Locations
3
France
Novartis Investigative Site
Bron, France
Novartis Investigative Site
Le Kremlin-Bicêtre, France
Novartis Investigative Site
Paris, France
Start Date
November 3, 2014
Primary Completion Date
August 31, 2018
Completion Date
August 31, 2018
Last Updated
May 19, 2020
NCT01676948
NCT00889863
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions